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Abstract
The Coronavirus disease 2019 (COVID-19) pandemic has grown to be a global public
health crisis with no safe and effective treatments available yet. Recent findings sug-
gest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coro-
navirus pathogen that causes COVID-19, could elicit a cytokine storm that drives
edema, dysfunction of the airway exchange, and acute respiratory distress syndrome
in the lung, followed by acute cardiac injury and thromboembolic events leading to
multiorgan failure and death. Mesenchymal stromal cells (MSCs), owing to their pow-
erful immunomodulatory abilities, have the potential to attenuate the cytokine storm
and have therefore been proposed as a potential therapeutic approach for which sev-
eral clinical trials are underway. Given that intravenous infusion of MSCs results in a
significant trapping in the lung, MSC therapy could directly mitigate inflammation,
protect alveolar epithelial cells, and reverse lung dysfunction by normalizing the pul-
monary microenvironment and preventing pulmonary fibrosis. In this review, we pre-
sent an overview and perspectives of the SARS-CoV-2 induced inflammatory
dysfunction and the potential of MSC immunomodulation for the prevention and
treatment of COVID-19 related pulmonary disease.
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1 | COVID-19 INDUCED DISEASE AND
INFLAMMATORY DYSFUNCTION
Coronavirus disease 2019 (COVID-19), a newly emerged respiratory
disease caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), has recently become a pandemic leading to innumer-
able deaths across the globe. SARS-CoV-2 is a novel beta-coronavirus
(a large RNA virus), that utilizes the viral S spike protein which
interacts with human angiotensin-converting enzyme 2 (ACE2) recep-
tor to gain entry to cells.1,2 The internalization of SARS-CoV-2 virus is
assisted by transmembrane protease serine 2 (TMPRSS2) protease.2
SARS-CoV-2 exhibits enhanced ACE2 receptor binding affinity and
stability for fast dissemination among diverse cells including type II
pneumocytes, bronchial cells, macrophages, monocytes, and enteric
cells.3 Consequently, the localization pattern of ACE2 receptors
strongly relates to tissues affected by SARS-CoV-2 leading to symp-
toms and organ dysfunction.1 In particular, SARS-CoV-2 exhibits a
high replication rate and infectivity in the human oral pharynx and
upper airway, due to high expression of ACE2 receptor in these areas.
Most patients with COVID-19 exhibit mild to moderate symptoms,
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and 73% infected patients are men.4 Approximately 15% to 20% pro-
gress to severe pneumonia and about 5% eventually develop acute
respiratory distress syndrome (ARDS), septic shock, and/or multiple
organ failure.1,4 Therefore, a comprehensive understanding of how
these severe symptoms develop could reveal promising strategies for
therapeutic intervention.
Severe COVID-19 infection is characterized by pneumonia,
lymphopenia, and a cytokine storm.5 This latter phenomenon is char-
acterized by an excessive inflammatory response, caused by a dys-
regulated immune system, which begins at a local site and then spills
over to the systemic circulation, affecting multiple organs. Cytokine
storm is not specific to SARS-CoV-2 infection; it has been also
observed initially in the context of graft-vs-host disease, as well as
other infectious diseases caused by cytomegalovirus, Epstein-Barr
virus, streptococcus, influenza virus, variola virus, and SARS-CoV.6
Moreover, it was also observed in noninfectious diseases and the
corresponding therapeutic interventions.7
SARS-CoV-2 infection induces the activation of both innate and
adaptive immune responses,5,8 leading to massive production of an
array of inflammatory factors, resulting in uncontrolled ramping up of
the immune response.9,10 Most severe COVID-19 patients exhibit ele-
vated serum levels of pro-inflammatory cytokines including interleukin
(IL)-1β, IL-2, IL-6, IL-7, IL-8, IL-17, granulocyte-colony stimulating fac-
tor, granulocyte-macrophage colony-stimulating factor, interferon
γ-induced protein 10 (IP10; CXCL10), monocyte chemoattractant pro-
tein 1 (MCP1, CCL2), macrophage inflammatory protein 1-α (MIP1α),
and tumor necrosis factor-α (TNF-α).4,5,8,9 A retrospective study of
150 COVID-19 patients indicated that elevated ferritin and IL-6 due
to hyperinflammation might be involved in mortality risk.11 Substan-
tially, high levels of cytokines may lead to cytokine release syndrome
(CRS), causing shock and tissue damage in vital organs.5,10 In particu-
lar, cytokine storm in COVID-19 patients has been shown to aggra-
vate acute cardiac injury comprising of myocarditis, acute heart
failure, and cardiac arrest.12
These markers of inflammation detected in the serum, are most
likely the end result of a chain of events starting in the lung itself. This
local immunological cascade is generally crucial to immunopathology
of other severe infections affecting deep tissues of the respiratory
tract, such as avian influenza virus or severe primary influenza virus
infections.13,14 Specifically, the cytokine storm in the lung is a hall-
mark of SARS-CoV-2 pathogenesis, resulting in extensive pulmonary
pathology including increased permeability of lung endothelial and
epithelial cells, interstitial edema, diffuse alveolar damage, dysfunction
of air-exchange, and ARDS (Figure 1).5,15,16 Usually, CRS is initiated
by macrophages, dendritic cells (DCs), natural killer (NK) cells and
T cells, owing to pathogen-associated molecular pattern activation.17
Indeed, it has been reported that bronchoalveolar fluid from patients
with severe COVID-19 had high concentrations of chemokines CCL2
and CCL7, which are potent monocyte recruiters, thus suggesting a
role for those cells in the pathophysiology of the disease. Notably,
mononuclear phagocytes represented 80% of bronchoalveolar fluid
cells in severe COVID-19 cases, 60% in mild cases, and only 40% in
healthy controls. In severe COVID-19 patients, there was also
depletion of tissue macrophages, an increase in inflammatory mono-
cyte derived macrophages18,19 and a general increment in the number
of neutrophils and leukocytes. Moreover, the prominent lymphopenia,
which develops in most COVID-19 patients, indicates an impairment
of immune system and further supports the evidence of innate immu-
nity as initiator of the cytokine storm.20 Nonetheless, adaptive
immune cells, namely T lymphocytes, may drive inflammation at later
disease stages,21 thus secondary hemophagocytic lymphohistiocytosis
may be another pathophysiological feature of notable attention.9,21
However, while the general concept of an excessive or uncontrolled
release of pro-inflammatory cytokines is well known, there remains
lack of good understanding of the molecular events that unleash the
cytokine storm as well as its respective prevention and therapeutic
strategies.6
It has been proposed that SARS-CoV-2 binds to the Toll-like
receptors (TLRs) leading to the synthesis and release of pro-
inflammatory IL-1, IL-6, and TNF-α as main mediators of the inflam-
mation pathway.22,23 Indeed, after the binding to the TLR, myeloid
differentiation primary response 88 (MyD88) or TIR domain-
containing adapter-inducing interferon-β (TRIF) activates tumor
necrosis factor receptor associated factor 6 (TRAF6), which in turn
stimulates caspase 1, inducing the cleavage of pro-IL-1 and the activa-
tion of the inflammasomes as well as tumor growth factor-β-activated
kinase and I kappa B kinase (IKK). This cascade ultimately initiates the
activation of nuclear factor-kappa B in the nucleus. Subsequently,
pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, initiate
the inflammatory processes in the lung, giving rise to the classic
COVID-19 symptoms.22,23 Moreover, in a proposed model based on
SARS-CoV-1, viral protein encoded by ORF8b directly interacts with
inflammasome NLRP3 (nucleotide-binding domain leucine-rich repeat
and pyrin domain containing receptor 3), which activates the adaptor
protein ASC and caspases 4, 5, and 11. This leads to a disruption of
the cell membrane and the release of the cell content to the extracel-
lular space, causing local inflammation.24 Furthermore, the binding of
SARS-CoV-2 to the ACE2 on the cell surface impairs its enzymatic
activity, thus resulting in increased levels of Angiotensin II (AngII) in
the extracellular space which, in turns, leads to higher levels of TNF-α
and IL-6 in the cell that upregulate NF-κβ, ultimately activating the
inflammasome.23 Finally, recruitment of macrophages to the site of
injury and phagocytosis of dead cells results in the release of ATP,
which binds to the P2X purinoceptor 7 (P2RX7) giving another impor-
tant contribution to the activation of the inflammasome.25 Also, the
increased calcium levels caused by the viral proteins results in
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lysosomal damage, thereby releasing cathepsins that, again, activate
the inflammasome.22
Several strategies to suppress the degree of immune storm have
been attempted to treat critically ill patients with COVID-19. In this
respect, as serum IL-6 plays an important role in CRS which correlates
with respiratory failure, ARDS, elevated serum C-reactive protein
(CRP), and poor clinical outcomes,26-28 tocilizumab, a IL-6 receptor
blocker, has been tested and shown to improve respiratory function in
21 patients with severe COVID-19.5 These encouraging results sug-
gest that neutralizing monoclonal antibodies against IL-6 or other pro-
inflammatory cytokines such as IL-1 and their receptors may provide
a novel strategy for counteracting the cytokine storm in COVID-19
patients. A great deal of effort has been devoted to targeting the host
response with a variety of anti-inflammatory drugs and adjunct
approaches, including corticosteroids, nonsteroidal anti-inflammatory
drugs,29 neutralizing monoclonal antibodies such as Lenzilumab and
Tocilizumab,30,31 statins,32 chloroquine and hydroxychloroquine, com-
plement inhibitors,33 and others.34 However, these therapeutic
approaches possess safety concerns due to their low specificity to
lung immunopathology.35
Despite multiple therapeutic strategies have been attempted, the
mortality of severely ill COVID-19 patients remains high and warrants
an urgent need of identifying a better therapeutic strategy against the
cytokine storm. The use of living cells as effectors offers intrinsic
advantages from a pharmacokinetic and pharmacodynamic point of
view, compared to the administration of conventional drugs. Cell ther-
apies render the effect localized at the site where the cell resides,
reducing the possibility of side effects at a distant site. Moreover, cells
have the possibility to persist in the tissue, allowing a longer-lasting
effect. Furthermore, their mechanism of action is often multifaceted
and involves different pathways simultaneously.36,37 Related to this,
cell-based therapies can offer additional mechanisms to dampen lung
inflammation by regulating the activation of specific cell types. For
example, CD200R expression on alveolar macrophages helps in
resolving lung inflammation during influenza virus infection by
restraining macrophage activity.38 Moreover, the production of anti-
inflammatory cytokines, mainly IL-10 by macrophages and certain
types of T (Th2 and regulatory T cells) and B cells, represents another
mechanism involved in regulating pro-inflammatory responses.7 In this
respect, mesenchymal stromal cells (MSCs) demonstrate a remarkable
immune-modulatory capacity in different settings and represent an
attractive option for the treatment of COVID-19 related cytokine
storm.
2 | MSC MEDIATED
IMMUNOMODULATION
In the last decade, cell-based therapies have emerged as promising
therapeutic options for many incurable diseases. Among different cell
platforms, MSCs raised a particular interest due to easy sourcing and
attractive features of plasticity, tropism for inflamed tissues, and a
high immunomodulatory potential.39 MSCs are characterized
phenotypically by the expression of certain cell surface markers,
including CD73, CD90, and CD105, and lack of expression of CD11b,
CD14, CD34, CD45, CD79, or HLA-DR, and functionally by the ability
to differentiate into mesenchymal lineages.40 Preclinical studies and
clinical trials have provided compelling evidence supporting their
immunomodulatory functions in the context of various conditions,
including graft-vs-host disease, autoimmune diseases, inflammatory
illnesses, myocardial infarction, lung injuries, liver cirrhosis, diabetes,
and cancer.41-43 MSCs modulate both innate and adaptive immunity,
influencing a wide range of effectors, including T cells, B cells, macro-
phages, neutrophils, NK cells, and DCs (Figure 2). The mechanisms
underlying anti-inflammatory and immunomodulatory effects which
ultimately lead to improvement of the aforementioned conditions are
exerted either via cell-to-cell contact or paracrine activity, affecting
recruitment, differentiation, proliferation, activation, and survival of
effector cells or promoting their polarization into anti-inflammatory
subtypes.43,44 Experimental evidence suggests that cell contact is
involved in the control of immune cells survival through Fas/FasL sig-
naling, their blockade through the stimulation of programmed cell
death protein 1 (PD-1)/ programmed-death ligand 1 (PD-L1) axis, the
suppression of DC generation by activation of the Notch pathway,
and abrogation of NK cells functions by the activation of the inhibi-
tory TLR4 receptor.43,44 On the other side, MSCs exert paracrine
action by releasing biologically active molecules, and shedding extra-
cellular vesicles, or exosomes, that contain a broad spectrum of cyto-
kines, chemokines, and growth factors.43 In a preclinical setup, MSC-
derived exosomes have demonstrated aptitude as an acellular alterna-
tive to cell-based therapy, against ARDS.45 Among these, the main
immunomodulatory players are prostaglandin E2 (PGE-2), indoleamine
2,3-dioxygenase (IDO), TNF, nitric oxide (NO), IL-1Rα, HLA-G, and IL-
10.43,46,47 Finally, MSCs can be manipulated ex vivo to integrate and
empower their features. In particular, it has been demonstrated exper-
imentally that MSCs preconditioned by hypoxia, oxidative stress, heat
shock, nutrient starvation, or genetic manipulation with immunomod-
ulatory molecules have the ability to increase their survival and
potency, and thereby enhancing the therapeutic efficacy.48,49
Although MSCs possess a marked immune-regulatory effect against
inflammatory and autoimmune disorders, it is widely acknowledged
that they are not immunosuppressive in nature. Instead, MSCs may
have different immunoregulatory effects depending on the immune
milieu and disease setting. For example, while MSCs are able to sup-
press compromising antiviral responses needed for disease
control,50,51 they can also exert differential effects on alloantigen and
virus specific T cells that retain the ability to proliferate and kill the
virus-infected cells.52 Moreover, an increased risk to (opportunistic)
infections has never been reported, as described in a recent meta-
analysis on almost 2700 patients treated by MSC for different
indications.53
A number of studies have demonstrated the preliminary safety
and efficacy of both MSCs and exosomes in alleviating comorbidities
associated with COVID-19.54-56 MSC-shed exosomes, owing to their
ability to endogenously repair and decrease the inflammatory reac-
tions involved in the morbidity and mortality of COVID-19, present a
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promising potential to be used following clinical evaluation. Thus,
MSCs represent a valuable and versatile cell platform which is able to
modulate the immune response at different levels. However, the
interplay between MSC and various elements of the immune system
is not fully understood and may result in controversial outcomes
depending on MSC sources, target cells, and the microenviron-
ment.43,44 A further advantage of applying MSCs is the possibility to
use an allogeneic source, thus circumventing the time lag needed to
produce a clinical grade product. Most importantly, the low levels of
expression of HLA class I molecules and lack of HLA class II and
costimulatory molecules57 enable their administration across HLA bar-
riers without preventive immune-ablative treatment.58 However,
when sought, measurable humoral alloimmunization in human sub-
jects receiving mismatched MSCs has been detected,59 although it
does not seem to affect their therapeutic efficacy. In this regard, it
should be pointed out that MSCs are now considered immune-evasive
and not immune-privileged as previously thought.60 Notwithstanding,
after more than a decade of clinical application of MSCs, an over-
whelming safety profile has been repeatedly documented,53 including
the absence of malignant transformation since they do not engraft
host tissues. Indeed, their mechanism of action does not depend on
their differentiation into specific end-organ cells, but rather on the
creation of an appropriate microenvironment, called “quasi niche”61
where both resident and immune cells are aided in re-establishing tis-
sue homeostasis.62 Finally, it was recently found that human MSCs
are SARS-CoV-2 infection resistant, likely due to the low ACE2 and
TMPRSS2 expression on their surface, and that they keep their IDO-1
production capacity in the presence of SARS-CoV-2.63 This represents
a unique strength when evaluating new treatment strategies in the
specific clinical setting of COVID-19. All these properties, together
with the absence of ethical controversies, make MSCs very attractive
for cell-based therapy.
3 | MSCs CAN ATTENUATE COVID-19
RELATED CYTOKINE STORM AND
COAGULOPATHY
One of the most harmful consequences of SARS-CoV-2 infection is
the excessive and aberrant host immune response, accompanied by a
cytokine storm and the subsequent ARDS, resulting in multiple organ
failure and death. By virtue of their powerful immunomodulatory abil-
ity, MSCs offer a promising innovative strategy for attenuating the
cytokine storm and ultimately improving patients' outcome
(Figure 3).10 After intravenous infusion, MSCs get trapped in the
inflamed lung and exert immunomodulatory function via direct inter-
action with respiratory epithelial cells and immune cells, or release of
a wide variety of soluble mediators, ultimately reducing the inflamma-
tion and protecting the alveolar epithelial cells.64-66 As discussed, it is
likely that the local immunological events in the deep tissues of the
lungs are crucial for the initiation of the cytokine storm and thus a
localized treatment might be, in theory more effective to stop the cas-
cade.18,19 In this regard, it should be emphasized that MSC
administration may be performed by using different routes: intrave-
nously with access from a peripheral or central vein, intra-arterial
depending on the target organ, but also directly in the damaged tissue
as in fistulizing Crohn's disease where local injections have proved
successful in inducing closure of fistula tracks refractory to standard
treatment.67 Additionally, delivery routes such as intrathecal, intra-
articular, and intradermal have been shown feasible in patients suffer-
ing from amyotrophic lateral sclerosis, osteoarthritis, and scleroderma,
respectively.68-70 It is conceivable therefore, that also in the case of
COVID-19 patients, intratracheal administration might work better.
Nonetheless, all the clinical trials so far use intravenous route of MSC
administration (Table 1) and feasibility and effectiveness of intra-
tracheal/bronchial administration of MSCs is unknown. To date, pre-
clinical studies have provided robust evidence for the effect of MSCs
on treating lung injury and ARDS, even though in vivo models still fail
to elucidate their precise mechanism of action. A common observa-
tion is that MSC exposure results in a decline of pro-inflammatory
cytokines including IL-1α, IL-1β, IL-6, IFN-γ, and TNF-α and an
increase in anti-inflammatory cytokines such as IL-4, IL-5, and IL-10.
The restored, noninflamed microenvironment aids in the repair of pul-
monary epithelial cell damage and promotes alveolar fluid clearance,
thus restoring lung function with enhanced alveolar air-space volume,
reduced alveolar thickening, and decreased markers of inflamma-
tion.5,40 Noticeably, ex vivo manipulation of MSCs can result in
improved function. In particular, preconditioning MSC with ARDS
serum has been shown to significantly increase the expression of IL-
10, IL-1Rα, and reduce the expression of pro-inflammatory media-
tors.71 In addition, adipose tissue-derived MSCs transduced to
express soluble IL-1 receptor-like-1 or bone marrow-derived MSCs
expressing ACE-2 significantly reduced lung injury index and levels of
pro-inflammatory cytokines in a murine model of non-SARS-CoV-2
acute lung injury.72,73 Interestingly, apart from the infusion of viable
cells, MSC secretome is emerging as a promising cell-free therapeutic
strategy for the treatment of acute and chronic lung diseases.45,74-77
A growing number of reports account for the use of MSC derivatives,
such as conditioned medium or extracellular vesicles, demonstrating
some initial positive effects which, if confirmed in more extensive
studies, might further extend the versatility of MSCs to treat inflam-
matory lung conditions (Table 2).45
The encouraging preclinical data indicating the suitability of MSCs
in controlling inflammatory responses in the lungs as well as in other
organs have led to their application in early stage clinical trials. These
trials have confirmed the ability of MSC to improve disease-
associated parameters in ARDS subjects78 with anti-inflammatory and
antiapoptotic effects.78 Furthermore, MSC administration protects
and reduces morphological and multiple organ dysfunction.78,79 A
phase IIa study including 60 patients with moderate to severe ARDS
showed intravenous infusion of MSC was safe but did not improve
the rate of 28-day mortality (30% vs 15%), suggesting that studies
with larger patient cohorts are necessary.80 A recently published
paper reported a clinical study for transplantation of allogeneic
menstrual-blood-derived MSCs for treating influenza H7N9-induced
ARDS in 17 patients.28 Results showed that MSC transplantation
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significantly lowered the mortality compared to control group (17.6%
vs 54.5%) without harmful effects.5,28 Given that H7N9 and COVID-
19 share similar complications (including ARDS, lung failure, and multi-
organ dysfunction), MSCs offer an innovative therapy for treating
COVID-19.4,28 While no firm conclusions may be drawn on the effi-
cacy and safety of MSC administration in ARDS, the encouraging
results of these trials have paved the way for using MSC-based immu-
nomodulation treatment as a suitable therapeutic approach for
COVID-19.
The endothelial damage and the activation of blood coagulation
are emerging as common phenomena in critical COVID-19 patients.
The virus appears to bind to the endothelial cells causing damage
especially in the microcirculation leading to platelet aggregation asso-
ciated with organ failure.81,82 In the context of MSC-based therapy,
this aspect needs careful consideration. Indeed, MSCs isolated from
different sources largely differ in their hemocompatibility depending
on the expression of tissue factor TF/CD142, a key trigger of the
extrinsic coagulation pathway, and receptors for complement activa-
tion products (eg, C3a, C5a).83-85 More in depth, compared to BM-
MSCs, AT- and PT-derived products demonstrate higher TF expres-
sion and reduced hemocompatibility, with substantial donor variation
and culture passage-dependent TF induction.83,86 Specifically, a
thromboembolic risk becomes evident when using MSCs into systemi-
cally activated/pro-inflammatory patients who do not receive anti-
coagulation treatment at the time of cell infusion.87 Moreover, freeze-
thawed MSCs trigger a strong instant blood-mediated inflammatory
reaction when washed with buffer containing human blood type AB
plasma instead of human serum albumin.88 It is strongly rec-
ommended to use regular low-dose anticoagulants and, possibly, to
perform standardized hemocompatibility testing in those MSC prod-
ucts that are intended for intravascular delivery. Nevertheless, the
largest meta-analysis on MSC in clinical settings did not report
increased thromboembolic risk.53 On the contrary, data demonstrated
that MSCs have the ability to reduce platelet adhesion and aggrega-
tion in a rat model of a vascular graft, which depended on cell-surface
heparan sulfate proteoglycans.89 In addition, MSC can inhibit platelet
activation and aggregation through CD73 ectonucleotidase activity,90
one of key MSC membrane markers. Hence, MSCs might be able to
play a crucial role in dampening both inflammation and
hypercoagulopathy status during SARS-CoV-2 related severe
pneumonia.
4 | MSC MEDIATED EPITHELIAL AND
VASCULAR PROTECTION
Recent studies carried out in both in vitro and in vivo models of influ-
enza respiratory infections have shown the protective effects of
MSCs on the alveolar-capillary barrier, the functional entity responsi-
ble for gas exchange that undergoes disruption during pathogen-
induced ARDS.91 MSCs were able to improve the dysregulated alveo-
lar fluid clearance and protein permeability induced by H5N1 and
H7N9 influenza viruses, by releasing soluble mediators that
upregulated sodium and chloride transporters.92 A single intravenous
infusion of BM-derived MSCs in H9N2-induced lung injury mice led
to reduction of mortality, lung edema, histologic injury, and
chemokines and cytokines levels in BALF and serum.93 Additionally,
UC-MSCs were more effective than human BM-derived MSCs at
restoring impaired alveolar fluid clearance and permeability in vitro
airway epithelial cell models.94 These effects seemed largely mediated
by secretion of an array of bioactive molecules, such as angiopoietin-1
(Ang-1), keratinocyte growth factor, and hepatocyte growth factor,
that act as antiapoptotic, pro-regenerative, and proangiogenic
factors.95
5 | CLINICAL EVIDENCE OF MSCs
THERAPY FOR COVID-19 INDUCED
INFLAMMATORY DYSFUNCTION
Currently, the www.ClinicalTrials.gov database, as accessed on
September 30, 2020, reports 2251 active COVID-19 clinical studies in
different phases of clinical testing and recruitment. Of these, 44 stud-
ies involve the use of MSCs for the management of COVID-19
(Table 1). A multicenter phase-III study is currently being conducted in
the United States using a MSC industrial preparation, Remestemcel-L
plus standard of care to treat ARDS associated with SARS-CoV2
infection (NCT04371393). This study is based on preclinical and clini-
cal evidence indicating that MSCs migrate to the lung and respond to
the pro-inflammatory lung environment by releasing anti-
inflammatory factors reducing the production of pro-inflammatory
cytokines while modulating regulatory T cells and macrophages to
promote resolution of inflammation. Mesoblast reported an 83% sur-
vival in ventilator-dependent COVID-19 patients with moderate/
severe ARDS, and 75% have successfully come off ventilator follow-
ing Remestemcel-L administration (Table 3).96
In the United Kingdom, the REALIST trial is in phase II and is test-
ing a single infusion of Orbcel-C, a human umbilical cord stem cell
product enriched with CD362 expressing cells for the management of
ARDS.54 In the completed part of the phase I REALIST trial, an infu-
sion of 400 million cells was achieved without any dose limiting toxic-
ity at day 7 and has been chosen as the dose for phase II clinical
testing. The MACoVIA study is a multicenter phase II/III clinical study
aimed at evaluating the safety and efficacy of Multistem MSC product
for the management of moderate to severe ARDS in COVID-19
patients. MultiStem is a cell therapeutic isolated from adult bone mar-
row approved for clinical use in patients with ischemic stroke.97
MSC from further sources are also being tested for clinical
COVID-19 management. The earliest of the trials embarked on by
Stemcells Arabia in Amman, Jordan, utilized intravenous infusion of
Wharton's Jelly (WJ) derived MSCs. This phase I study, slated to com-
plete in September 2020, enrolled five patients with COVID-19 illness
and a dose of 1 × 106 body weight WJ-MSC/kg was administered for
three times 3 days apart. Renmin Hospital of Wuhan University in
China is currently evaluating the safety and efficacy of dental pulp
derived MSCs as a part of a phase I/II randomized controlled clinical
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study.98 Time to clinical improvement is the main outcomes indicator
and is considered as the time taken to reduce disease severity by two
stages following treatment.98 The Wellness trial in Mexico utilizes
autologous adipose tissue-derived MSCs for COVID-19 management.
A three-dose regimen of Celltex-AdMSC will be administered, about
200 million cells per dose; the safety, tolerability and efficacy will be
evaluated as a part of this multicenter study.
A recently conducted clinical study by Leng et al at the Beijing
YouAn Hospital, China, demonstrated the use of bone marrow-
derived MSCs for the management of pneumonia associated with
COVID-19. Ten patients with worsening respiratory condition were
recruited with seven patients assigned to the treatment arm and three
to the placebo arm.10,99,100 A dose of 1 × 106 MSC/kg body weigh
was used, and results report a reduction of symptoms within 2 to
4 days postinfusion and a majority of patients showed negative for
the SARS-CoV-2 nucleic acid test 2 days after MSC administration
with no apparent treatment-related adverse effects.99 This small study
provided evidence that the intervention was feasible, safe, and has
the potential to improve functional outcomes. It is conceivable that
the main mechanisms of MSC action underlying clinical improvement
was linked to the immunosuppressive capacities of MSCs to attenuate
over-activated cytokine-secreting immune cells.99,100 Indeed, this pro-
cess was accompanied by an increased number of peripheral lympho-
cytes as well as of both regulatory DCs and T cells, decrease of CRP,
and regression of over-activated cytokine-secreting immune cells.99
MSCs decreased the levels of TNF-α and increased the concentration
of anti-inflammatory protein IL-10.99,100 RNA-sequencing revealed
that the infused MSCs in patients resulted in downregulating expres-
sion of ACE2 and TMPRSS2.99 This pilot study demonstrated that
MSC therapy inhibited the overactivation of the immune system and
promoted endogenous repair by improving the lung microenviron-
ment after the SARS-CoV-2 infection.99,100 Hope Biosciences has
recently obtained clearance from the FDA to initiate a phase 2 study
to evaluate the efficacy and safety of allogeneic adipose tissue-
derived MSCs (HB-adMSCs) as treatment for patients with COVID-
19. The study purpose is to evaluate the safety and efficacy of four
intravenous infusions of either placebo or HB-adMSCs in subjects
with COVID-19. HB-adMSC have been previously approved for clini-
cal use in patients with traumatic brain injury.101
Another case report described the recovery of a COVID-19
patient with severe inflammation symptoms after treated with allo-
genic human umbilical cord MSCs (hUCMSCs).102 A dose of 5 × 107
hUCMSCs was administered to the patient three times with a 3-day
interval. Four days after the end of the treatment, the patient was
released from ICU with the remission of the inflammation symptoms
and without developing side effects.102 A growing number of MSC-
based clinical trials will continue to be carried out to validate the ther-
apeutic utility of MSCs in COVID-19 management. The basic rationale
for all MSC-related therapies seems to be dependent on the potential
to alleviate the cytokine storm caused by SARS-CoV2 infection and
early evidence from the data published by Leng et al99 and Liang
et al102 supported the remission of inflammation symptoms in
patients with COVID-19.
6 | PERSPECTIVES AND FUTURE
DIRECTIONS
COVID-19 has emerged as a global health care crisis and several stud-
ies have demonstrated that hyperinflammation associated with high
levels of circulating cytokines induced by SARS-CoV-2 is a major con-
tributing factor of disease severity and death in patients.9-11 By virtue
of their immunomodulatory and anti-inflammatory features, MSCs
appear to be a promising therapeutic candidate for COVID-19 man-
agement. While waiting for outcomes from impending clinical studies,
MSCs could be used as a compassionate strategy for managing criti-
cally ill COVID-19 patients with the intent to reduce morbidity and
mortality.10,64,103 Despite encouraging early clinical data, there remain
scientific concerns regarding the use of MSCs as a therapeutic inter-
vention for COVID-19, as detailed here below.
The main sources of MSCs in active clinical trials range from
umbilical cord (Wharton's jelly, UC), umbilical cord blood, adipose tis-
sue, bone marrow, menstrual blood, and dental pulp.15 Although initial
clinical results spark enthusiasm for adipose tissue-derived MSCs as a
therapeutic option in COVID-19 linked respiratory conditions,104 the
best MSC source is yet to be determined. One key aspect in deciding
the most suited MSC option could be their vulnerability to SARS-
CoV-2 once infused into a patient with an ongoing infection, as well
as how this would affect the potential beneficial effects. Two studies
have demonstrated that overexpression of ACE2 in murine BM-MSCs
offered additional anti-inflammatory and endothelial-protective
effects against endotoxin-induced lung injury in mice.73,105 Impor-
tantly, both studies showed detectable basal levels of cellular and
secreted ACE2 by unmodified BM-MSCs as measured by polymerase
chain reaction, Western blot, and enzyme-linked immunosorbent
assay. Similarly, lentiviral-transduced ACE2-overexpressing human
UC-MSCs were more effective than constitutively ACE2-expressing
UC-MSCs in a rat acute lung ischemia reperfusion injury model.106
Hence, a real dilemma of choosing the best MSCs is to determine a
fine line between an optimal level of ACE2 for lung protection and
the minimum vulnerability to SARS-CoV-2, which will require well-
designed preclinical studies.
Developing MSCs as a potential treatment option for COVID-19
patients is still challenging due to the lack of suitable preclinical
models.107 To fill this gap, a number of studies are currently being
developed. Moreover, it is imperative to better understand the mech-
anisms underlying MSCs modulation of the process of COVID-19
infection108 before translating it into the clinic. Preclinical studies
could also resolve the queries related to the anti-inflammatory func-
tion of MSCs, either acting directly against viral infection or by stimu-
lating antiviral T-cell actions.109 Preclinical data generated in relevant
mouse models of COVID-19 infection may help to better stratify the
patients to appropriate MSC dosing and administration schedule.110
Considering that animal models may be difficult to fully reproduce the
complicated pathophysiological processes and internal environment
changes in severe COVID-19 patients, the data from early clinical
studies are crucial. However, a longer time is needed to accurately
monitor MSC-treated patients with respect to safety and efficacy in
6 MSC IMMUNOMODULATION AND COVID-19
ongoing clinical studies, as well as accounting the emerging coagula-
tion issues in these patients. For instance, a recent clinical report
described an emerging chronic tissue injury related to COVID-19111
which could motivate the use MSCs as treatment due to its
antifibrotic properties.36
MSC can also act through secreted factors43 which might offer a
new therapeutic approach in treating COVID-19 patients due to their
broad pharmacological effects.74 MSC secretome offers the ease of
manipulation at relatively lower costs.74 MSCs can also be genetically
modified to release specific bioactive molecules able to counteract a
pathological situation. For instance, as the viral receptor ACE2 and
TMPRSS2 contribute to COVID-19 progression, engineering MSCs
with immunomodulatory molecules to target these receptors in the
process of SARS-CoV-2 internalization may provide an alternative
therapeutic option. In this regard, given that the IFN/TNF-related
apoptosis-inducing ligand (TRAIL) axis is subjected to a complex mod-
ulation during the process of acute respiratory viral infection including
coronaviruses,112 MSCs could be genetically modified to therapeuti-
cally target IFN/TRAIL signaling. Previous studies have shown that
viral infection can upregulate TRAIL receptors and enhance sensitivity
to TRAIL-induced apoptosis,113,114 whereas the increase of TRAIL
may induce lymphocyte apoptosis in SARS-CoV infection.114 Further-
more, an alternative mechanism of action of TRAIL is the induction of
autophagy, which contributes to viral clearance by transferring viral
materials to cellular endosomes and subsequently activating adaptive
immune system.115 Therefore, engineering MSCs to express TRAIL
may present promise for future clinical applications in COVID-19
management,116 as it has previously been reported in cancer ther-
apy.117,118 Alternative options have been conceived using MSCs
delivering leukemia inhibitory factor to antagonize COVID-19 cyto-
kine storm.16
Taken together, we discussed the nature of the inflammatory
responses that have been detected in patients with COVID-19 and
outlined the scientific rationale as well as several preliminary findings
to corroborate that MSCs emerge as a promising therapeutic candi-
date to manage this condition. To ensure that MSC intervention
reaches its full potential, research and development will need to focus
on understanding the complexity of COVID-19 pathophysiology and
precise therapeutic mechanisms of action to optimize the therapeutic
procedures and stratify patient cohorts. Multidisciplinary and vigorous
efforts by interventional physicians, basic scientists, and other health
care professionals could realize the promise of MSCs as a valuable
asset for COVID-19 treatment.
Although further investigations are needed on the use of wild-
type and gene-modified MSCs for the treatment of COVID-19, the
preliminary findings highlight therapeutic benefit. The use of MSCs
for ARDS associated with COVID-19 is highly experimental. Patients
suffering from SARS-CoV-2 severe pneumonia reported amelioration
of respiratory function as a consequence of MSC infusion due to yet
unclear modulation of cytokine storm and protection of epithelial and
endothelial cells. Studies suggest that the source of the MSCs play a
crucial role in attenuating the COVID-19 infection induced cytokine
storm. A better understanding of the implicated bio-active molecules
would not only improve the rational of MSC for COVID-19 but addi-
tionally help in understating the pathophysiology of this still obscure
and dismal condition, ultimately decreasing a surprisingly high mortal-
ity rate by cell-based therapeutic.
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TABLE 1 Active MSC clinical trials for COVID-19 as listed at www.ClinicalTrials.gov (accessed on September 30, 2020)
ClinicalTrials.
gov identifier Study title
Stem












1 × 106 cells/kg IV Native I Recruiting
NCT04428801 Autologous adipose-derived




200 × 106 IV Native II Not yet
recruiting
NCT04336254 Safety and efficacy study of
allogeneic human dental pulp





3 × 107 IV Native I/ II Recruiting
NCT04429763 Safety and efficacy of
mesenchymal stem cells in





1 × 106 cells/kg IV Native II Not yet
recruiting
NCT04416139 Mesenchymal stem cell for
acute respiratory distress




1 × 106 cells/ kg IV Native II Recruiting
NCT04315987 NestaCell mesenchymal stem
cell to treat patients with
severe COVID-19 pneumonia
NestaCell 20 × 106 cells IV Modified II Not yet
recruiting
NCT04348435 A randomized, double-blind,
placebo-controlled clinical
trial to determine the safety








200 × 106 cells IV Modified II Enrolling
by
invitation
NCT04366323 Clinical Trial to assess the
safety and efficacy of
intravenous administration of
allogeneic adult mesenchymal
stem cells of expanded
adipose tissue in patients





80 × 106 cells IV Native II Recruiting
NCT04349631 A Clinical Trial to determine the








Not mentioned IV Native II Enrolling
by
invitation
NCT04302519 Novel Coronavirus induced





1 × 106 cells /kg IV Native I Not yet
recruiting
NCT04252118 Mesenchymal stem cell
treatment for pneumonia
3 × 107 cells IV Native I Recruiting
(Continues)
SONG ET AL. 11
TABLE 1 (Continued)
ClinicalTrials.
gov identifier Study title
Stem




















1 × 106 cells/kg IV Native I/ II Not yet
recruiting
NCT04288102 Treatment with human
umbilical cord-derived
mesenchymal stem cells for




4 × 107 cells IV Native II Active, not
recruiting
NCT04273646 Study of human umbilical cord
mesenchymal stem cells in




5 × 106 cells/kg IV Native Not applicable
Not yet
recruiting
NCT04437823 Efficacy of intravenous






5 × 105 cells/ kg IV Native II Recruiting
NCT04339660 Clinical research of human
mesenchymal stem cells in





1 × 106 cells/kg IV Native I/ II Recruiting








Not mentioned IV Native I/ II Enrolling
by
invitation
NCT04371601 Safety and effectiveness of
mesenchymal stem cells in
the treatment of pneumonia




1 × 106 cells /kg IV Native I Active, not
recruiting







100 × 106 MSCs and
extracellular vesicles
(EVs)
IV Native II/III Recruiting




100 × 106 cells IV Native I/ II Completed
NCT04362189 Efficacy and safety study of
allogeneic HB-adMSCs for
the treatment of COVID-19
Adipose
MSC
100 × 106 cells IV Native II Not yet
recruiting




3 × 106 cells/kg IV Native I/ II Recruiting
NCT04299152 Stem cell educator therapy treat




Not mentioned IV Native II Not yet
recruiting
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TABLE 1 (Continued)
ClinicalTrials.
gov identifier Study title
Stem







NCT04390152 Safety and efficacy of
intravenous Wharton's jelly
derived mesenchymal stem
cells in acute respiratory




50 × 106 IV Native I/ II Not yet
recruiting
NCT04293692 Therapy for pneumonia patients





0.5 × 106/kg IV Native Not applicable
Withdrawn





1.5 × 106/kg IV Native II Not yet
recruiting






3, 5 or 10 × 106 cells/kg IV Native I/ II Recruiting







Not mentioned IV Native II Not yet
recruiting
NCT04371393 MSCs in COVID-19 ARDS Bone
marrow
MSC
2 × 106/kg IV Native III Recruiting




100 × 106 IV Native I/II Withdrawn
NCT04390139 Efficacy and safety evaluation
of mesenchymal stem cells
for the treatment of patients




1 × 106 cells/Kg IV Native I/ II Recruiting







75 × 106 IV Native II Not yet
recruiting




1 × 106 cells/kg IV Native I/ II Not yet
recruiting









Not mentioned IV Modified I Not yet
recruiting




Not mentioned IV Native Not applicable
Recruiting
NCT03042143 Repair of acute respiratory





400 × 106 IV Native I/ II Recruiting
(Continues)
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TABLE 1 (Continued)
ClinicalTrials.
gov identifier Study title
Stem







NCT04345601 Mesenchymal stromal cells for







2 × 106 cells/kg IV Native I Not yet
recruiting







1 × 106/kg IV Modified II Recruiting
NCT04269525 Umbilical cord (UC)-derived
mesenchymal stem cells





3.3 × 1067 IV Native II Recruiting
NCT04333368 Cell therapy using umbilical
cord-derived mesenchymal




1 × 106/kg IV Native I/ II Not yet
recruiting
NCT04389450 Double-blind, multicenter, study
to evaluate the efficacy of




Not mentioned IV Modified II Recruiting





Not mentioned IV Modified II/III Recruiting
NCT04276987 A pilot clinical study on
inhalation of mesenchymal






2 × 108 nano vesicles IV Native I Completed
Abbreviations: ARDS, Acute respiratory distress syndrome; MSC, mesenchymal stromal cells; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
14 MSC IMMUNOMODULATION AND COVID-19
TABLE 2 Studies testing the effects of MSC derivatives on inflammation
Disease models Origin of MSCs MSC derivatives Inflammatory mediators References
Acute respiratory distress
syndrome (ARDS)
BM-MSCs EVs Increased expression of interleukin
(IL)-10
119




ARDS and ALI BM-MSCs Conditioned
medium, EVs
Decreased secretion of TNF-α and
IL-8
121
ALI BM-MSCs EVs Decreased TNF-α and increased
IL-10
122






Decreased expression of serum
amyloid A3 (SAA3)
124
ARDS BM-MSCs Culture medium Increased expression of interleukin
(IL)-10 and IL-1 receptor
antagonist
103






Culture medium Increased IL-10 expression,
prevented IL-33, TLR-4, IL-1β,
and IFN-γ induction, decreased
pro-inflammatory cytokines
(TNF-α, IL-6, and macrophage
inflammatory protein 2)
65
Cecal ligation and puncture
model of sepsis
WJ-MSCs Culture medium Decreased expression of nuclear
factor κB and of cytokines;




Severe COVID-19 pneumonia) MSCs Clinical grade MSCs Decreased TNF-α and increased
IL-10
54
ALI Modified MSCs with ACE2 Culture medium Downregulated ICAM-1, VCAM-1,
TNF-α, and IL-6
102
ALI Modified UC-MSCs with ACE2 Culture medium Decreased expression of MDA,
GSSG, TNF-α, IFN-γ, TGF-β,
IL-1, IL-2, IL-6, collagen type 1
mRNA, MMPs and TIMPs as
well as hydroxyproline
concentration, and upregulation
of SOD, GSH and ACE2 and IL-
10.
103
Abbreviations: EVs, extracellular vesicles; MSC, mesenchymal stromal cells.
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TABLE 3 Cytokines and cytokine receptors elevated in the plasma/serum of COVID-19 patients
Immune modulator N (number of patients) References
Pro-inflammatory cytokines
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F IGURE 1 Schematic showing pathophysiological features of COVID-19 infected lung. SARS-CoV-2 enters target cells and induces extensive
pulmonary pathology including increased permeability of lung endothelial and epithelial cells, pulmonary edema, diffuse alveolar damage, and
dysfunction of air-exchange. Figure drawn with BioRender (https://biorender.com/). SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2
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F IGURE 2 Immunomodulatory interactions between mesenchymal stem cells (MSCs) and immune cells. MSCs exert immunomodulatory
functions mainly via interactions with immune cells (including T cells, B cells, NK cells, macrophages, monocytes, dendritic cells, and neutrophils)
through cell-to-cell contacts and paracrine activity (mainly by secretome). Figure drawn with BioRender (https://biorender.com/). ICAM-1,
intercellular adhesion molecule-1; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFN, interferon; IL, interleukin; NK, natural killer; PD-L1,
programmed death ligand 1; PD-L2, programmed death ligand 2; PGE2, prostaglandin E2; TGF-β, transforming growth factor-β; TNF-α, tumor
necrosis factor-α; VEGF, vascular endothelial growth factor
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F IGURE 3 Potential mechanism of MSC action in COVID-19 infected patients. SARS-CoV-2 enters cells through receptor-mediated
endocytosis via interactions with cell surface protein angiotensin-converting enzyme II (ACE2) receptor with the assistance of TMPRSS2
protease, thus triggering a complex immune response involved in T cells, dendritic cells, NK cells, and macrophages. These cells release high
amounts of cytokines and chemokines responsible for the cytokine storm, leading to symptoms and major organ dysfunction. Engineering MSCs
with immunomodulatory molecules enhance the efficacy of homing to damaged tissues or cells and attenuate the cytokine storm, ultimately
improving patients' outcome. Figure drawn with BioRender (https://biorender.com/). G-CSF, granulocyte-colony stimulating factor; GM-CSF,
granulocyte- macrophage colony-stimulating factor; IL, interleukin; IP10, interferon gamma-induced protein 10; MCP1, monocyte
chemoattractant protein 1; MIP1α, macrophage inflammatory protein 1-alpha.; MSCs, mesenchymal stem cells; NK, natural killer; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor
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Potential mechanism of MSC action in COVID-19 infected patients. SARS-CoV-2 enters cells through receptor-mediated endocytosis via interac-
tions with cell surface protein angiotensin-converting enzyme II (ACE2) receptor with the assistance of transmembrane protease serine
2 (TMPRSS2) protease, thus triggering a complex immune response involved in T cells, dendritic cells, natural killer cells and macrophages. Engi-
neering MSCs with immunomodulatory molecules enhance the efficacy of homing to damaged tissues or cells and attenuate the cytokine storm,
ultimately improving patients& outcome.
